Screener
Evolus EOLS R&D
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Evolus in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Evolus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:56 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053468
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Gross profit | 57,180 | 45,320 | 106,077 | 91,975 |
| Operating expenses: | ||||
| Selling, general and administrative | 57,052 | 56,675 | 109,033 | 113,315 |
| Research and development | 1,892 | 1,837 | 4,132 | 4,049 |
| Revaluation of contingent royalty obligation payable to Evolus Founders | 1,250 | (3,914) | 1,236 | (1,763) |
| Depreciation and amortization | 1,529 | 932 | 3,067 | 1,756 |
| Total operating expenses | 61,723 | 55,530 | 117,468 | 117,357 |
| Loss from operations | (4,543) | (10,210) | (11,391) | (25,382) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Evolus's R&D?
- Evolus (EOLS) reported R&D of $1.89M in Q2 2026.
- How has Evolus's R&D changed year-over-year?
- Evolus's R&D increased by 3.0% year-over-year, from $1.84M to $1.89M.
- What is the long-term trend for Evolus's R&D?
- Over 4 years (2021 to 2025), Evolus's R&D has grown at a 46.8% compound annual growth rate (CAGR), from $2.06M to $9.58M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Evolus's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude